Commentary

Video

Clinical Efficacy With Ponatinib in the PHALLCON Trial for Ph+ ALL

Author(s):

Ibrahim Aldoss, MD, City of Hope Comprehensive Cancer CenterElias Jabbour, MD, MD Anderson Cancer Center

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the efficacy with ponatinib observed in the PHALLCON trial of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Related Videos
Saro H. Armenian, DO, MPH
A panel of 3 experts on nasopharyngeal carcinoma
Saro H. Armenian, DO, MPH
Chad Tang MD, MD Anderson
Bora Lim, MD, MD Anderson
Areej El-Jawahri, MD, associate director, Cancer Outcomes Research and Education Program, director, Bone Marrow Transplant Survivorship Program, associate professor, medicine, Massachusetts General Hospital
Idoroenyi Amanam, MD
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD
Related Content
Shyam A. Patel, MD,PhD
September 27th 2024

Meta-Analysis Reveals Potential Role of Clonal Hematopoiesis on Allogeneic and Autologous HSCT Outcomes

Ravi Salgia, MD, PhD, professor, chair, Department of Medical Oncology & Therapeutics Research, Arthur & Rosalie Kaplan Chair in Medical Oncology & Therapeutics Research, City of Hope
September 2nd 2024

Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC

Bora Lim, MD, of MD Anderson Cancer Center
September 25th 2024

Adjuvant Ribociclib Approval Expands Access to CDK4/6 Inhibition in High-Risk HR+/HER2– Breast Cancer

Oncology Unplugged
August 21st 2024

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

Kelly Chien, MD
September 22nd 2024

Tapotoclax Demonstrates Safety, Yields Anti-Leukemic Effects but No Responses in MDS Following HMAs

Stephan Braun, MD, PhD
September 18th 2024

FDA Grants Fast Track Designation to ICT01 Plus Azacitidine/Venetoclax in Treatment-Naive AML